SEC Company Response from Eledon Pharmaceuticals, Inc. (ELDN) (CIK 0001404281) (ELDN) — Jul 30, 2018
Eledon Pharmaceuticals, Inc. (ELDN) (CIK 0001404281)
Date: July 30, 2018 · CIK: 0001404281 · Accession: 0001193125-18-231910
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226286
Letter
Novus Therapeutics, Inc.
19900 MacArthur Blvd., Suite 550
Irvine, California 92612
(949) 238-8090
July 30, 2018
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Irene Paik
Re: Novus Therapeutics, Inc.
Registration Statement on Form S-3
Filed July 23, 2018
File No. 333-226286
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, Novus Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-3 filed by the Company (the “Registration Statement”) be accelerated to 4:00 p.m., Eastern Daylight Time, on, July 31, 2018 or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
Novus Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Novus Therapeutics, Inc. 19900 MacArthur Blvd., Suite 550 Irvine, California 92612 (949) 238-8090 July 30, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Irene Paik Re: Novus Therapeutics, Inc. Registration Statement on Form S-3 Filed July 23, 2018 File No. 333-226286 Ladies and Gentlemen: Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, Novus Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-3 filed by the Company (the “Registration Statement”) be accelerated to 4:00 p.m., Eastern Daylight Time, on, July 31, 2018 or as soon thereafter as practicable. [Signature page follows] Very truly yours, Novus Therapeutics, Inc. /s/ Gregory J. Flesher Gregory J. Flesher Chief Executive Officer cc: Ryan A. Murr, Gibson, Dunn & Crutcher LLP